What are the considerations for using GLP-1 (Glucagon-like peptide-1) receptor agonists, such as liraglutide (Victoza) or semaglutide (Ozempic), in a patient with chronic Hepatitis B, fatty liver disease, and hypothyroidism on levothyroxine (T4) therapy?
Together, these processes compromise ATP generation, aggravate structural remodeling, and accelerate HF progression (Wang et al., 2021)
Certificates of Analysis (COAs) are made available to support transparency and documentation requirements for research use
Metabolites were separated using an Acquity UPLC BEH C8 1.7 m column (Waters, Milford, MA, USA) with mobile phase comprising 10 mmol/L ammonium acetate and 0.05% heptafluorobutyric acid in Milli-Q water (solution A) and 10 mmol/L ammonium acetate and 0.05% heptafluorobutyric acid (dissolved in 50 mL Milli-Q water) in methanol (solution B)